Emerging approaches to dyslipidemia management beyond LDL-c

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
AHA 2024
Bempedoic acid reduces adverse limb events in patients with PAD
- Marc Bonaca, MD
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
AHA 2024
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Early and sustained non-HDL-c target achievement after MI
Early and sustained non-HDL-c target achievement after MI
Hyperlipidemia
Early and sustained non-HDL-c target achievement after MI
- Jessica Schubert, MD
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
MinuteCE®
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
0.75 program credits
- Pasquale Perrone-Filardi, MD, PhD
0.75 program credits